Welcome to our dedicated page for Agenus SEC filings (Ticker: AGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Agenus Inc. (NASDAQ: AGEN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a publicly traded immuno-oncology developer. As a filer under the Securities Exchange Act of 1934, Agenus uses Forms 8-K, 10-Q, 10-K and proxy materials to report financial results, clinical and corporate milestones, and shareholder actions related to its cancer immunotherapy programs.
Recent Form 8-K filings illustrate how these documents track material events. Agenus has furnished quarterly financial results for periods in 2025, reported on its annual meeting of stockholders and voting outcomes on director elections and equity plans, and described a promissory note agreement with a Zydus Lifesciences subsidiary tied to the planned sale of its Emeryville and Berkeley biologics manufacturing facilities. Other 8-Ks outline progress on the broader asset purchase, stock purchase and license agreements with Zydus, including updates on the Committee on Foreign Investment in the United States (CFIUS) review process.
For investors analyzing Agenus, periodic reports such as Forms 10-Q and 10-K (when available) are central to understanding the company’s financial condition, risk factors and research and development focus in immuno-oncology. These filings typically discuss the BOT+BAL clinical program, broader pipeline of antibody therapeutics, adoptive cell therapies and adjuvants, and the company’s development capabilities and collaborations.
On Stock Titan, each new Agenus filing is captured from EDGAR and paired with AI-powered summaries designed to highlight the most important points—such as key terms of financing arrangements, updates on the Zydus collaboration, or changes in capital structure. Users can also review Forms 4 and related ownership reports to monitor insider transactions in AGEN shares. This centralized view helps readers navigate complex SEC documents and quickly identify information relevant to Agenus’ immuno-oncology strategy, clinical progress and corporate governance.
Agenus Inc. reported that Chairman and Chief Executive Officer Garo H. Armen received 4,316 shares of common stock on 12/12/2025 as payment of his salary in stock, in lieu of cash, at his request and with Compensation Committee approval. The shares were valued at $3.79, the closing price of Agenus common stock on December 12, 2025, and are fully vested on the date of issuance under the company’s 2019 Equity Incentive plan. After this transaction, Dr. Armen directly holds 302,401 Agenus shares, in addition to indirect holdings through IRA accounts and a trust and partnership structure.
Agenus Inc. (AGEN) reported that Chairman and CEO Garo H. Armen received part of his compensation in stock instead of cash. On 11/14/2025, he was issued 3,769 shares of common stock as salary for the pay period ending that date, under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan. The shares were valued using the $4.34 closing price of Agenus common stock on 11/14/2025 and are fully vested on the date of issuance. Following this transaction, Dr. Armen beneficially owns 294,498 shares directly, with additional indirect holdings reported through IRA accounts and entities in which he has a pecuniary interest.
Agenus Inc. reported Q3 2025 results. Total revenues were
On the balance sheet, cash and cash equivalents were
Management disclosed that, despite post-quarter cash actions—including a
Agenus Inc. reported its quarterly results for the period ended September 30, 2025 and furnished the accompanying press release as Exhibit 99.1. The company submitted this information under Item 2.02 of Form 8-K.
The disclosure is designated as “furnished,” not “filed,” meaning it is not subject to Section 18 liabilities and is only incorporated by reference if expressly stated. Agenus’s common stock trades on the Nasdaq Global Market under the symbol AGEN.
Agenus Inc. (AGEN) reported an insider transaction: Chairman and CEO Garo H. Armen acquired 4,120 shares of common stock on 10/31/2025 at $3.97 per share. The shares were issued as salary paid in stock, fully vested upon issuance, under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan.
After the transaction, Dr. Armen’s direct beneficial ownership was 290,729 shares. He also holds 31,298 shares indirectly through IRA accounts and 28,950 shares indirectly via a GRAT and a partnership, as noted in the filing.
Agenus (AGEN) reported an insider stock compensation event. Chairman and CEO Garo H. Armen received 4,216 shares of Common Stock on 10/17/2025 as salary paid in stock, in lieu of cash, under the Amended and Restated 2019 Equity Incentive plan. The grant was valued using the $3.88 closing price on 10/17/2025 and the shares were fully vested at issuance.
Following the transaction, Dr. Armen beneficially owns 286,609 shares directly, plus 31,298 shares indirectly held in IRA accounts and 28,950 shares indirectly via trust/partnership interests as described in the footnotes.
Agenus Inc. entered into a Promissory Note Agreement with Zydus Pharmaceuticals (USA) Inc. for up to
Proceeds will support operating expenses at Agenus’s Emeryville and Berkeley facilities during the fourth quarter of 2025 and to make certain payments related to assets covered by the asset purchase agreement. The facility-related fourth-quarter funding will be forgiven and not repaid if the transactions with Zydus are completed. As collateral, Agenus pledged 822,910 shares of MiNK Therapeutics, Inc. common stock, which are expected to be released once the note is repaid or forgiven.
Garo H. Armen, Chairman and Chief Executive Officer of Agenus Inc. (AGEN), received 3,951 shares of common stock as salary in lieu of cash, issued under the company's equity plan. The shares were issued at the closing price of
Agenus Inc. (AGEN) director Thomas L. Harrison received 5,780 shares of common stock on 10/01/2025 under the company's Board Compensation Election Policy, electing to take director fees in equity rather than cash. The shares were issued at an average price of $5.01, which the filer says is the average closing price for the quarter preceding issuance. After this transaction, Mr. Harrison beneficially owns 22,079 shares. The Form 4 was filed by an attorney-in-fact on 10/03/2025, and no derivative transactions are reported.
Timothy R. Wright, a director of Agenus Inc. (AGEN), reported acquiring 1,704.928 deferred stock units on 10/01/2025 under the company’s Amended and Restated Directors' Deferred Compensation Plan. Each deferred stock unit converts to one share of common stock on a 1-for-1 basis, and the filing shows 21,872.43 shares beneficially owned by Mr. Wright after the transaction. The filing notes that a prior tranche of deferred stock units was valued at $5.01 per unit on 7/01/2025, and states the October 1, 2025 unit price is the average closing price for the company’s common stock during the calendar quarter immediately preceding that date. The units are typically distributed under the Plan once the director ceases service.